PATENT CLAIM ANALYSIS

Application Number: 16183352
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "311000"]

Abstract:
Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.

Claim (Index 2):
A method for treatment of a solid tumor(s) in a patient, comprising administering to the patient an effective amount of at least one leukotriene inhibitor selected from the group consisting of: compounds selected from montelukast, zafirlukast, and pranlukast; pharmaceutically acceptable salts of said compounds; and pharmaceutically acceptable solvates of said compounds and said salts.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 98.0
- Lexical Diversity: 1.72059
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14786089', '15680493', '14495725', '15262143', '12648078']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.765143500446039
- 35 USC 102 Novelty (BERT): 0.6456964403512421
- Combined Prediction Score: 0.7531987944365593
- Mean Citation Score: 372.660292
- Max Citation Score: 627.94794
- Similarity Product: 586.322829908266

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test